Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro

Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PIs) against SARS-CoV-2 and their interactions with remdesivir, the only direct-act...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammeltoft, Karen A., Zhou, Yuyong, Duarte Hernandez, Carlos R., Galli, Andrea, Offersgaard, Anna, Costa, Rui, Pham, Long V., Fahnøe, Ulrik, Feng, Shan, Scheel, Troels K. H., Ramirez, Santseharay, Bukh, Jens, Gottwein, Judith M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370243/
https://www.ncbi.nlm.nih.gov/pubmed/34097489
http://dx.doi.org/10.1128/AAC.02680-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370243/
https://www.ncbi.nlm.nih.gov/pubmed/34097489
http://dx.doi.org/10.1128/AAC.02680-20

Ejemplares similares